Day: December 24, 2025

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 23, 2025 (GLOBE NEWSWIRE) — Canterra Minerals Corporation (TSXV:CTM) (OTCQB:CTMCF) (FSE:DXZB) (“Canterra” or the “Company”) is pleased to announce the closing of its previously announced private placement (see news releases dated December 4, 2025 and December 19, 2025) consisting of Critical Minerals flow-through shares and National flow-through shares for total gross proceeds of $5,705,361.51. (the “Private Placement”). Pursuant to the Private Placement the Company issued 10,980,000 Critical Minerals flow-through shares at a price of $0.25 per share (each, a “CMFT Share”) for gross proceeds of C$2,745,000. Each CMFT Share comprises one common share of the Company (each, a “Common Share”) issued as a flow-through...

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) remains the U.S. brand name for PK deficiency indication  AQVESME expected to be available in late January 2026, following AQVESME REMS program implementation Company will host investor conference call and webcast tomorrow, December 24 at 8:00 a.m. ETCAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved AQVESME™ (mitapivat), an oral pyruvate kinase (PK)...